Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Spectrum Pharmaceuticals has increased its manufacturing capacity of Fusilev (levoleucovorin) for injection and build ready-to-ship inventory reserves.
Subscribe to our email newsletter
The company expects to maintain sufficient reserves of oncology drug supplies and multiple manufacturing facilities approved by the FDA.
Spectrum president and chief executive officer Rajesh Shrotriya said the company embarked on a manufacturing plan to expand capacity that can supply the demand of the entire patient population.
"Access to multiple manufacturing facilities approved by the FDA greatly reduces the risk of supply interruptions, giving physicians and patients the strong reassurance of availability they need," Shrotriya added.
Fusilev is indicated for use in combination chemotherapy with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer.
The folate analog is approved as a ready-to-use solution (Fusilev Injection), and as freeze-dried powder (Fusilev for Injection).